{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:57:47Z","timestamp":1779321467727,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.nmd.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:20:45Z","timestamp":1718169645000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Statins in hereditary myopathies: to give or not to give"],"prefix":"10.1016","volume":"41","author":[{"given":"Zohar","family":"Argov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.06.004_bib0001","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3233\/JND-230064","article-title":"Dyslipidemia in Muscular Dystrophy: A Systematic Review and Meta-Analysis","volume":"10","author":"Sun","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"10.1016\/j.nmd.2024.06.004_bib0002","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","article-title":"Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients","volume":"92","author":"Newman","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0003","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.metabol.2008.09.019","article-title":"Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?","volume":"58","author":"Glueck","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.nmd.2024.06.004_bib0004","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.2007.075523","article-title":"Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study","volume":"67","author":"Sailler","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.06.004_bib0005","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.06.004_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2796.2009.02173.x","article-title":"Statins and amyotrophic lateral sclerosis\u2013the level of evidence for an association","volume":"266","author":"S\u00f8rensen","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.nmd.2024.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0008","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.nmd.2024.06.004_bib0009","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212588","article-title":"Mitochondrial disorders and drugs: what every physician should know","volume":"8","author":"Orsucci","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.nmd.2024.06.004_bib0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome","volume":"94","author":"Chariot","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.nmd.2024.06.004_bib0011","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archinte.166.14.1519","article-title":"Presymptomatic neuromuscular disorders disclosed following statin treatment","volume":"166","author":"Tsivgoulis","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.nmd.2024.06.004_bib0012","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking MELAS syndrome. A case report","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pediatrneurol.2008.09.002","article-title":"Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation","volume":"39","author":"Tay","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0014","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1258\/000456303322326542","article-title":"The case of stainless statins","volume":"40","author":"Barth","year":"2003","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.nmd.2024.06.004_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/0004563041201554","article-title":"McArdle's disease diagnosed following statin-induced myositis","volume":"41","author":"Livingstone","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.nmd.2024.06.004_bib0016","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1590\/S0004-282X2007000500020","article-title":"McArdle disease with rhabdomyolysis induced by rosuvastatin: case report","volume":"65","author":"Lorenzoni","year":"2007","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.nmd.2024.06.004_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.06.004_bib0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nmd.2024.06.004_bib0019","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00003643-200407000-00013","article-title":"Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment","volume":"21","author":"Krivosic-Horber","year":"2004","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00228-014-1776-9","article-title":"Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives","volume":"71","author":"Hedenmalm","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0021","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","article-title":"Statin-disclosed acid maltase deficiency","volume":"258","author":"Voermans","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.nmd.2024.06.004_bib0022","first-page":"252","article-title":"Metabolic impairments in patients with myotonic dystrophy type 2","volume":"37","author":"Vujnic","year":"2018","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0023","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-152-7-201004060-00025","article-title":"Another side to statin-related side effects","volume":"152","author":"Knoblauch","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmd.2024.06.004_bib0024","first-page":"429","article-title":"The Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy","volume":"15","author":"Deichmann","year":"2015","journal-title":"Ochsner J"},{"key":"10.1016\/j.nmd.2024.06.004_bib0025","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jacl.2017.08.014","article-title":"Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin\/kexin type 9 inhibitor, alirocumab (Praluent)","volume":"11","author":"Shakir","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0026","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.ajpath.2014.04.013","article-title":"Abnormal splicing of NEDD4 in myotonic dystrophy type 2: possible link to statin adverse reactions","volume":"184","author":"Screen","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0027","first-page":"359789","article-title":"SLCO1B1 variants and statin-induced myopathy-a genomewide study","author":"Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.06.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217831120","article-title":"Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone","volume":"120","author":"Yogev","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2024.06.004_bib0029","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ajhg.2023.04.006","article-title":"Bi-allelic variants in HMGCR cause an autosomal-recessive progressive limb-girdle muscular dystrophy","volume":"110","author":"Morales-Rosado","year":"2023","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2024.06.004_bib0030","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mus.20575","article-title":"Sporadic rippling muscle disease unmasked by simvastatin","volume":"34","author":"Baker","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.06.004_bib0031","article-title":"A novel missense mutation in CAV3 gene in an Italian family with persistent hyperCKemia, myalgia and hypercholesterolemia: Double-trouble","volume":"191","author":"Bruno","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.nmd.2024.06.004_bib0032","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMc0908215","article-title":"Neuromuscular symptoms and elevated creatine kinase after statin withdrawal","volume":"362","author":"Echaniz-Laguna","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.06.004_bib0033","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2024.06.004_bib0034","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3390\/ijms22042070","article-title":"Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence","volume":"22","author":"Camerino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2024.06.004_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","volume":"5","author":"Mohassel","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"10.1016\/j.nmd.2024.06.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2024.06.004_bib0037","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1755-5922.2011.00267.x","article-title":"Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge","volume":"30","author":"Fung","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.nmd.2024.06.004_bib0038","article-title":"Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid","volume":"22","author":"Yarrarapu","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.nmd.2024.06.004_bib0039","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic Acid: for Whom and When","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr Atheroscler Rep"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662400138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662400138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T03:16:14Z","timestamp":1722050174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089662400138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":39,"alternative-id":["S096089662400138X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.06.004","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins in hereditary myopathies: to give or not to give","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}